These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23361368)

  • 21. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
    Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
    J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dichloroacetate induces tumor-specific radiosensitivity in vitro but attenuates radiation-induced tumor growth delay in vivo.
    Zwicker F; Kirsner A; Peschke P; Roeder F; Debus J; Huber PE; Weber KJ
    Strahlenther Onkol; 2013 Aug; 189(8):684-92. PubMed ID: 23793865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.
    Selvakumaran M; Amaravadi RK; Vasilevskaya IA; O'Dwyer PJ
    Clin Cancer Res; 2013 Jun; 19(11):2995-3007. PubMed ID: 23461901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
    Lee FY; Covello KL; Castaneda S; Hawken DR; Kan D; Lewin A; Wen ML; Ryseck RP; Fairchild CR; Fargnoli J; Kramer R
    Clin Cancer Res; 2008 Dec; 14(24):8123-31. PubMed ID: 19088027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
    Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
    Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
    Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
    Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.
    Davies S; Dai D; Pickett G; Thiel KW; Korovkina VP; Leslie KK
    Oncol Rep; 2011 Mar; 25(3):855-62. PubMed ID: 21240464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.
    Xie Y; Hicks MJ; Kaminsky SM; Moore MA; Crystal RG; Rafii A
    Gynecol Oncol; 2014 Nov; 135(2):325-32. PubMed ID: 25108232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dichloroacetate blocks aerobic glycolytic adaptation to attenuated measles virus and promotes viral replication leading to enhanced oncolysis in glioblastoma.
    Li C; Meng G; Su L; Chen A; Xia M; Xu C; Yu D; Jiang A; Wei J
    Oncotarget; 2015 Jan; 6(3):1544-55. PubMed ID: 25575816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
    Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
    Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.
    Kuang R; Jahangiri A; Mascharak S; Nguyen A; Chandra A; Flanigan PM; Yagnik G; Wagner JR; De Lay M; Carrera D; Castro BA; Hayes J; Sidorov M; Garcia JLI; Eriksson P; Ronen S; Phillips J; Molinaro A; Koliwad S; Aghi MK
    JCI Insight; 2017 Jan; 2(2):e88815. PubMed ID: 28138554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
    Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
    Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
    Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB
    Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.